BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Australia

Australia’s Monash University Launches Boston Hub to Accelerate Global Biotech Partnerships

Top‑50 global university deepens its North America and Europe collaborations to fast‑track drug discovery and health innovation. Monash University, Au...

October 06, 2025 | News

Teijin and Cell Therapies Forge a Cross-Border Alliance to Accelerate Cell and Gene Therapy Access Between Japan and Australia

As the cell and gene therapy (CGT) sector moves from scientific promise to large-scale reality, collaboration between nations with strong translational and...

October 06, 2025 | News | By arcilla.fran@biopharmaapac.com

Cell Therapies and Teijin Forge Strategic MoU to Build Asia-Pacific Cell and Gene Therapy Infrastructure

Cell Therapies Pty Ltd. (“Cell Therapies”) and Teijin Limited announced that they have signed a Memorandum of Unders...

October 02, 2025 | News

Lumonus Partners With Smarter Radiation Oncology® to Expand AI-Driven, Standardised Cancer Care Worldwide

Lumonus, a healthcare technology company transforming cancer care with its AI-powered platform, announced a multi-year agreement with Smarter Radiation Onc...

September 30, 2025 | News

CorestemChemon Phase 3 ALSummit Trial Shows Subgroup Benefit of Neuronata-R® in ALS

CorestemChemon Inc. announced that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® (lenzumestrocel) an autolo...

September 22, 2025 | News

Skyhawk’s SKY-0515 Shows 62% Reduction in Mutant Huntingtin at Day 84 in Huntington’s Disease Trial

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral dose Additional finding...

September 18, 2025 | News

US, China and Australia Begin Phase 2 Trial of Atom Therapeutics’ ABP-745 for Acute Gout Flares

ABP-745 is an oral small molecule drug with potential applications, for other inflammatory conditions such as cardiovascular disease Atom T...

September 17, 2025 | News

Pfizer Advances Australian-Discovered KAT6 Inhibitor PF-07248144 into Phase 3 Trial for Advanced Breast Cancer

Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinica...

September 16, 2025 | News

Kazia’s Paxalisib Disrupts Circulating Tumour Cell Clusters in HER2-Positive Metastatic Breast Cancer Study

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program...

September 12, 2025 | News

Zhimeng Biopharma Secures China’s Green Light for Phase 2 Trial of Next-Gen Epilepsy Drug CB03-154

Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, ...

September 12, 2025 | News

Telix Doses First Patient In Phase 3 BiPASS™ Trial Evaluating Illuccix® And Gozellix® For Prostate Cancer Diagnosis

Telix Pharmaceuticals Limited announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix&re...

September 11, 2025 | News

AGC Biologics Seattle Site Achieves New Heights in Manufacturing Excellence

Manufacturing excellence positions Seattle site as premier destination for mammalian and microbial biologic production in thriving Pacific Northwest life...

September 11, 2025 | News

XtalPi and PharmaEngine Advance AI-Designed PRMT5 Inhibitor PEP08 into Phase 1 Trials for Solid Tumours

XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaborati...

September 10, 2025 | News

The State of Biotech and Life Science Jobs in Asia Pacific – 2025

In 2025, Asia-Pacific has emerged as the fastest-growing hub for biotech and life sciences employment, fuelled by a powerful combination of government supp...

September 09, 2025 | Report

Stay Connected